Opus Genetics (IRD) Interest Expenses (2011 - 2026)

Opus Genetics' (IRD) quarterly Interest Expenses came in at $100000.0 in Q1 2026, up 212.5% on a QoQ basis from $32000.0 in Q4 2025.

Opus Genetics (IRD) Interest Expenses (2011 - 2026) Analysis & Trends

Opus Genetics (IRD) has 14 years of Interest Expenses data on file, last reported at $100000.0 in Q1 2026.

On a quarterly basis, Interest Expenses changed N/A year-over-year to $100000.0 in Q1 2026; TTM through Mar 2026 was $232000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $40.0 million, changed N/A from the prior year.
Interest Expenses for Q1 2026 stood at $100000.0, up from $32000.0 in the prior quarter.
Over the last five years, Interest Expenses for IRD reached as high as $100000.0 in Q3 2025 and fell as low as $4000.0 in Q2 2022.
Historically, Interest Expenses has averaged $48200.0 across 3 years, with a median of $32000.0 in 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Interest Expense (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-42,141.15
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	32.89 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	16.81 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	420.30 Mn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	28.30 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	1.17 Bn
10	Opus Genetics	3.27 Mn	-56.73 Mn	-	100,000.00

Download Data